- Home
- ZIP vs TYRA Comparison
ZIP vs TYRA Comparison
Compare ZIP & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- TYRA
- Stock Information
- Founded
- ZIP 2010
- TYRA 2018
- Country
- ZIP United States
- TYRA United States
- Employees
- ZIP N/A
- TYRA N/A
- Industry
- ZIP Diversified Commercial Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ZIP Consumer Discretionary
- TYRA Health Care
- Exchange
- ZIP Nasdaq
- TYRA Nasdaq
- Market Cap
- ZIP 499.5M
- TYRA 422.6M
- IPO Year
- ZIP 2021
- TYRA 2021
- Fundamental
- Price
- ZIP $5.51
- TYRA $8.92
- Analyst Decision
- ZIP Hold
- TYRA Strong Buy
- Analyst Count
- ZIP 5
- TYRA 6
- Target Price
- ZIP $7.80
- TYRA $30.50
- AVG Volume (30 Days)
- ZIP 1.1M
- TYRA 353.6K
- Earning Date
- ZIP 05-08-2025
- TYRA 05-08-2025
- Dividend Yield
- ZIP N/A
- TYRA N/A
- EPS Growth
- ZIP N/A
- TYRA N/A
- EPS
- ZIP N/A
- TYRA N/A
- Revenue
- ZIP $474,001,000.00
- TYRA N/A
- Revenue This Year
- ZIP N/A
- TYRA N/A
- Revenue Next Year
- ZIP $12.69
- TYRA N/A
- P/E Ratio
- ZIP N/A
- TYRA N/A
- Revenue Growth
- ZIP N/A
- TYRA N/A
- 52 Week Low
- ZIP $4.74
- TYRA $6.42
- 52 Week High
- ZIP $11.25
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ZIP 44.70
- TYRA 45.95
- Support Level
- ZIP $5.24
- TYRA $8.23
- Resistance Level
- ZIP $5.71
- TYRA $8.80
- Average True Range (ATR)
- ZIP 0.44
- TYRA 0.70
- MACD
- ZIP 0.01
- TYRA 0.19
- Stochastic Oscillator
- ZIP 46.55
- TYRA 75.30
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.